<DOC>
	<DOCNO>NCT00189722</DOCNO>
	<brief_summary>This study evaluate efficacy safety tacrolimus patient asthma .</brief_summary>
	<brief_title>Inhaled Tacrolimus , Add-on Inhaled Corticosteroids &amp; Long Acting B2 Agonists Moderate Severe Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Diagnosis asthma Patients treat inhaled corticosteroid long act beta 2 agonist FEV1 ( forced expiratory volume 1 second ) &gt; 50 % 80 % Respiratory infection within 2weeks Asthma exacerbation within 6 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Immunosuppressant</keyword>
	<keyword>Anti-asthmatic drug</keyword>
	<keyword>Administration , inhalation</keyword>
</DOC>